O

Open Orphan PLC
LSE:ORPH

Watchlist Manager
Open Orphan PLC
LSE:ORPH
Watchlist
Price: 10 GBX 5.26% Market Closed
Market Cap: 67.1m GBX

Operating Margin
Open Orphan PLC

12.7%
Current
-9%
Average
3.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
12.7%
=
Operating Profit
6.1m
/
Revenue
48.5m

Operating Margin Across Competitors

No Stocks Found

Open Orphan PLC
Glance View

Open Orphan Plc provides pharmaceutical development services. The firm is engaged in the testing of vaccines and antivirals using human clinical trials. The firm has a presence in the United Kingdom, Ireland, France and Netherlands. The Company, through its subsidiary hVIVO Limited, is also engaged in the data platform business. hVIVO Limited has built up databases of infectious disease progression data and the Company is populating its Open Orphan Health Data platform with hVIVO data. The firm also operates through its subsidiary Venn Life Sciences, which is an integrated drug development partner. Venn Life Sciences offers a combination of drug development consultancy, clinical trial design and execution to create, plan and execute drug development programs for its customers.

ORPH Intrinsic Value
Not Available
O
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
12.7%
=
Operating Profit
6.1m
/
Revenue
48.5m
What is the Operating Margin of Open Orphan PLC?

Based on Open Orphan PLC's most recent financial statements, the company has Operating Margin of 12.7%.

Back to Top